BioSpace News Archive

Celltrion Group announced the launch of its Phase I human clinical trial investigating a potential antiviral antibody treatment for patients with COVID-19.

Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DB102 (enzastaurin) being de

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. (" Fairhaven "), thu

Today, Westfall Technik is announcing a new partnership with Polycarbin—a software enabled biomedical plastic recycling company that has developed a method for diverting single-use scientific plastics from landfills, incinerators and recycling it back into the hands of scientists and clinicians as circular economy products

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, and the American Spine Registry™ (ASR), a national quality improvement registry for spine care, today announced that they have entered into a multi-year sponsorship

Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty yea

X-Vax Technology, Inc. (X-VAX ® ), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced the appointment of Isaac Blech as Vice Chairman of the company’s board of directors. As a co-founder of X-VAX, Mr. Blech previously served on the company’s Board until De

Zoom and Webex video conferencing applications from Vuzix provide COVID-19 business continuity support through one-to-one and one-to-many video calling

Sensient Technologies Corporation reported diluted earnings per share of 72 cents in the second quarter of 2020 compared to diluted earnings per share of 81 cents in the second quarter of 2019.

Cyclerion Therapeutics, Inc. announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead, presented on “Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies” at the Annual Biomarkers in Alzheimer’s Disease Summit that was held virtually on July 15, 2020.